Novo Nordisk Partners With Anthropic to Accelerate AI‑Driven Drug Discovery Using Claude

Novo Nordisk announced a collaboration with Anthropic to employ the Claude large‑language model in its drug‑discovery pipeline, aiming to speed identification of promising compounds, and the Danish company, known for diabetes treatments, expects the AI to streamline target validation and reduce laboratory cycles.

Anthropic provides Claude, an AI system trained on scientific literature and molecular data, which Novo plans to integrate with its chemistry platforms to generate candidate structures, suggest synthesis routes, and predict biological activity.

Claude is expected to improve early‑stage success, as analysts note AI‑driven programs can reach up to a 90 % Phase I success rate, while typical industry rates sit near 30 %, potentially cutting development time and cost.

Industry observers say the partnership signals growing confidence in generative AI for pharma, noting that companies like Novartis have already accelerated drug discovery timelines with AI platforms, and could set a benchmark for other firms seeking to modernize research with advanced language models.